Literature DB >> 15297205

Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor.

A L Leiser1, A M Hamid, R Blanchard.   

Abstract

INTRODUCTION: Endometrial stromal tumors with sex-cord-like elements are relatively rare. We report a case of this neoplasm with prolactin as a tumor marker for recurrent disease. We also report response of recurrent disease to progesterone and aromatase inhibitor. CASE REPORT: A 48-year-old woman was diagnosed with Stage I endometrial stroma sarcoma with sex-cord component at the time of hysterectomy for presumed fibroid uterus. One and a half years later, she presented with recurrent disease in the abdomen associated with breast tenderness, galactorrhea, and an elevated prolactin level. She received three cycles of BEP (Bleomycin, Etoposide, Cisplatin) with partial response and followed by an optimal debulking procedure. Two out of a six additional planned cycles of BEP were administered with complete tumor response and normalized prolactin level. Second recurrence, 9 months later, again presented with galactorrhea and rising prolactin. Disease was progressive through three cycles of Docetaxel and Gemcitabine therapy, but had an objective response to treatment with anastrozole and megestrol acetate. Prolactin level normalized. Two years later there is stable disease and the patient remains symptom-free. DISCUSSION: Endometrial stromal sarcoma with sex-cord stromal component may be hormonally functional. Similarly to pure endometrial stromal sarcomas, they may respond to hormonal treatment, and further study is warranted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297205     DOI: 10.1016/j.ygyno.2004.03.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

1.  Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.

Authors:  Kentaro Nakayama; Masako Ishikawa; Yutaka Nagai; Nobuo Yaegashi; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-03-10       Impact factor: 3.402

2.  Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature.

Authors:  Hyewon Ryu; Yoon-Seok Choi; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

Review 3.  HE4 as a biomarker for ovarian and endometrial cancer management.

Authors:  Jinping Li; Sean Dowdy; Tracy Tipton; Karl Podratz; Wei-Guo Lu; Xing Xie; Shi-Wen Jiang
Journal:  Expert Rev Mol Diagn       Date:  2009-09       Impact factor: 5.225

4.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

Review 5.  Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques.

Authors:  Patricia Baker; Esther Oliva
Journal:  J Clin Pathol       Date:  2007-03       Impact factor: 3.411

6.  Conservative management of endometrial stromal sarcoma at stage III: A case report.

Authors:  Ruiying Dong; Hongluan Mao; Peihai Zhang
Journal:  Oncol Lett       Date:  2014-06-26       Impact factor: 2.967

7.  Letrozole as second-line hormonal treatment for recurrent low-grade endometrial stromal sarcoma: A case report and review of the literature.

Authors:  Kohei Nakamura; Kentaro Nakayama; Masako Ishikawa; Noriyoshi Ishikawa; Hiroshi Katagiri; Atsuko Katagiri; Tomoka Ishibashi; Emi Sato; Kohji Iida; Razia Sultana; Satoru Kyo
Journal:  Oncol Lett       Date:  2016-09-26       Impact factor: 2.967

Review 8.  Treatment of early uterine sarcomas: disentangling adjuvant modalities.

Authors:  Flora Zagouri; Athanasios-Meletios Dimopoulos; Stelios Fotiou; Vassilios Kouloulias; Christos A Papadimitriou
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

9.  Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Authors:  Carmen Balañá; Enrique de Álava; Ruth Sardinha; Teresa Hernández; Susana Fraile; Francesc Tresserra; August Vidal; Maria Carmén Gómez; Aurora Astudillo; Nieves Hernández; Javier Saenz de Santamaría; Jaume Ordi; Luis Gonçalves; Rafael Ramos
Journal:  Clin Sarcoma Res       Date:  2013-03-07

Review 10.  Proteomic Biomarkers for the Detection of Endometrial Cancer.

Authors:  Kelechi Njoku; Davide Chiasserini; Anthony D Whetton; Emma J Crosbie
Journal:  Cancers (Basel)       Date:  2019-10-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.